fludarabine has been researched along with mk-8776 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Borsky, M; Brychtova, Y; Bryja, V; Collakova, J; Dzimkova, M; Hylse, O; Janovska, P; Jaskova, Z; Kasparkova, M; Kohoutek, J; Oltova, A; Paruch, K; Trbusek, M; Verner, J; Vesely, P; Zaprazna, K; Zemanova, J | 1 |
1 other study(ies) available for fludarabine and mk-8776
Article | Year |
---|---|
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Mitosis; Mutation; Nucleosides; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine | 2016 |